peppersite
Pharmaceutical

SLU-PP-322

SLU-PP-322 is an estrogen-related receptor (ERR) agonist research compound studied in mitochondrial-metabolism research models.

Researched for
Recovery
Not yet audited

We have not published an audit on SLU-PP-322. Everything below is reference material, not our own reading of the literature, treat it as a starting point for questions, not as a grade.

How it is thought to work

SLU-PP-332 is a synthetic small-molecule pan-agonist of the estrogen-related receptors (ERRα, ERRβ, and ERRγ) that activates transcription factors controlling mitochondrial biogenesis, fatty acid oxidation, and aerobic gene programs, mimicking the effects of endurance exercise. [Source: Peptide Dosing Protocols]

SLU-PP-332 is a synthetic molecule that activates the same cellular switches (ERR receptors) that endurance exercise activates, prompting cells to build more mitochondria and burn more fat, but it does this pharmacologically rather than through physical training, which is why it is called an exercise mimetic.

Reported side effects

In mouse studies SLU-PP-332 showed no overt toxicity at the doses tested, but there is zero human safety data, and community users have informally reported appetite changes, sleep disruption, a stimulatory feeling, and increased resting heart rate.

Who should avoid it

Anyone who is pregnant, breastfeeding, under 18, has cancer, heart disease, liver or kidney problems, or is subject to WADA drug testing should avoid SLU-PP-332, and anyone else considering it should do so only under qualified clinician oversight given the complete absence of human safety data.

What gets monitored

Resting heart rate and blood pressure should be tracked periodically due to community reports of heart-rate changes. [Source: Peptide Dosing Protocols]

What sources report

Reference, not a recommendation

These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for SLU-PP-322 or for anything else, and nothing below has been checked against the study it came from.

Standard: 50 mg (1 tablet) · Low: ≤1.5 mg · High: 100 mg (2 tablets)
Frequency
once daily6 weeks IP dosing (Burris-lab standard) Improved ejection fraction; reduced fibrosis; increased survival in the TAC model.
Route
oral
Reported by
Peptide Dosing Protocols
What it says(secondary reference; provider confirmation required). Half-life: half-life, there is no validated missed-dose rule. The standard dosing for SLU-PP-332 is 50 mg taken once daily.
Reconstitution, as reported
  • 5 mg vial reconstituted with 2 mL BAC water (2,500 mcg/mL) and a daily 500 mcg subcutaneous draw, a common community pattern, not a clinically validated dose.

Common questions

What is SLU-PP-332 and what is it commonly researched for?

SLU-PP-332 is a synthetic small-molecule pan-ERR agonist developed in the Thomas Burris lab, often described as an exercise mimetic.

What is the starting dose of SLU-PP-332?

There is no human-validated starting dose; community patterns suggest doses ranging from 250 mcg to 1.5 mg once daily.

How are SLU-PP-332 tablets typically dosed?

SLU-PP-332 is commonly carried as a 50 mg oral tablet in a 60-tablet bottle.

What is the difference between SLU-PP-332 tablets and injectable vials?

Tablets are easier to handle and dose by bottle count, while injectable vials are used in animal studies.

What is SLU-PP-332's half-life?

A formal human pharmacokinetic half-life has not been published.

How do you reconstitute SLU-PP-332 injection vials?

For a 5 mg vial, add 2 mL of bacteriostatic water to achieve a concentration of 2,500 mcg/mL.

Check 5 mg in 2 mL in the calculator →

Is SLU-PP-332 FDA-approved?

No, SLU-PP-332 is not approved by the FDA for any indication.

Sources

  1. 01Billon C, Sitaula S, Banerjee S, Welch R, Elgendy B, Hegazy L, et al. Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity. ACS Chemical Biology (2023)
  2. 02Billon C, Schoepke E, Avdagic A, Chatterjee A, Butler A, Elgendy B, et al. A Synthetic ERR Agonist Alleviates Metabolic Syndrome. Journal of Pharmacology and Experimental Therapeutics (2024)
  3. 03Xu W, Billon C, Li H, Wilderman A, Qi L, Graves A, et al. Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function. Circulation (2024)
  4. 04Wang XX, Myakala K, Libby AB, Krawczyk E, Panov J, Jones BA, et al. Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney. American Journal of Pathology (2023)
  5. 05MedChemExpress SLU-PP-332 | ERR Agonist product data sheet. MedChemExpress (2024)
  6. 06Cayman Chemical SLU-PP-332 product data sheet (CAS 303760-60-3). Cayman Chemical (2024)
  7. 07Shahien M, Elgendy B, Hegazy L, Patouret R, Walker JK, Burris TP. Development of synthetic agonists of estrogen-related receptors (ERRs) based on an aniline-based pan-agonist scaffold. Journal of Medicinal Chemistry (precursor scaffold context) (2023)
  8. 08Frontiers in Physiology editorial team Targeting ERRs to counteract age-related muscle atrophy associated with physical inactivity: a pilot study. Frontiers in Physiology (2025)
  9. 09Nasri H. New hopes on 'SLU-PP-332' as an effective agent for weight loss with indirect kidney protection efficacy; a nephrology point of view. Journal of Renal Endocrinology (2024)
  10. 10PubChem PubChem entry for SLU-PP-332 (CAS 303760-60-3). PubChem / NCBI (2024)
  11. 11ClinicalTrials.gov Registry search for 'SLU-PP-332' confirming no registered or completed human trials. ClinicalTrials.gov (2026)
  12. 12World Anti-Doping Agency WADA Prohibited List — class S4.5 metabolic modulators (ERR agonists as a class). WADA (2026)
Links

The reference sections above are imported from our compound knowledge base, which classes the evidence for SLU-PP-322 as emerging. That classification is the knowledge base’s, not ours, our own grade appears only where an audit is linked above. Research use only; nothing here is medical advice or a protocol.

Studied for the same things
5-Amino-1MQ

5-Amino-1MQ is a small molecule studied for its potential to help the body shrink fat cells and raise NAD+ levels without cutting appetite.

BPC-157

BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in gastric juice. Studied in tissue-repair and regeneration research models.

Cartalax

Peptide bioregulator referenced for connective tissue support.

Cerluten

Peptide bioregulator referenced for nervous system support.

CJC-1295 / Ipamorelin (No Dac)

Combination research blend of CJC-1295 (no DAC) and Ipamorelin. Studied as a GHRH/GHRP combination in growth-hormone-axis research.

Endoluten

Peptide bioregulator referenced for pineal support.